News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Dupont Jakob
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
4
| Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 392,461 options to buy
@ $1.6, valued at
$627.9k
|
|
| 08/25/2023 |
4
| Dupont Jakob (Director) has filed a Form 4 on Apexigen, Inc.|
Txns:
| Disposed/sold 34,084 options to buy
@ $4.59, valued at
$156.4k
Disposed/sold 20,489 options to buy
@ $0
Disposed/sold 100,000 options to buy
@ $2.65, valued at
$265k
|
|
| 08/25/2023 |
4
| Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 5,879 options to buy
@ $26.61, valued at
$156.4k
Granted 3,534 options to buy
@ $26.61, valued at
$94k
Granted 17,250 options to buy
@ $15.37, valued at
$265.1k
|
|
| 08/25/2023 |
3
| Dupont Jakob (Director) has filed a Form 3 on Pyxis Oncology, Inc. |
| 08/24/2023 |
3/A
| Dupont Jakob (Director) has filed a Form 3/A on Apexigen, Inc. |
| 03/06/2023 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 5,074 shares
@ $3.627, valued at
$18.4k
|
|
| 11/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/19/2022 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 3,873 shares
@ $5.318, valued at
$20.6k
|
|
| 03/03/2022 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Granted 78,506 shares
@ $0
Sold 2,221 shares
@ $9.856, valued at
$21.9k
Granted 147,573 options to buy
@ $10.21, valued at
$1.5M
|
|
| 02/14/2022 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $16, valued at
$80k
Exercised 5,000 options to buy
@ $9.58, valued at
$47.9k
|
|
| 01/05/2022 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $16.01, valued at
$80.1k
Exercised 5,000 options to buy
@ $9.58, valued at
$47.9k
|
|
| 12/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/18/2021 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 2,199 shares
@ $17.1169, valued at
$37.6k
|
|
| 11/04/2021 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $16.41, valued at
$82.1k
Exercised 5,000 options to buy
@ $9.58, valued at
$47.9k
|
|
| 08/19/2021 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Sold 2,152 shares
@ $12.532, valued at
$27k
|
|
| 05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2020 |
4
| Dupont Jakob (EVP, Head of R&D) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Granted 46,250 shares
@ $0
Granted 277,500 options to buy
@ $9.58, valued at
$2.7M
|
|
| 05/19/2020 |
3
| Dupont Jakob (EVP, Head of R&D) has filed a Form 3 on Atara Biotherapeutics, Inc. |
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/31/2019 |
4
| Dupont Jakob (Chief Medical Officer) has filed a Form 4 on Gossamer Bio, Inc.|
Txns:
| Sold 1,994 shares
@ $15.8145, valued at
$31.5k
Sold 40,000 shares
@ $15.0001, valued at
$600k
Exercised 1,994 options to buy
@ $10.71, valued at
$21.4k
Exercised 40,000 options to buy
@ $10.71, valued at
$428.4k
|
|
| 03/26/2019 |
4
| Dupont Jakob (Chief Medical Officer) has filed a Form 4 on Gossamer Bio, Inc.|
Txns:
| Granted 65,000 options to buy
@ $22.1, valued at
$1.4M
|
|
| 02/07/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/11/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/12/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/08/2016 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Sold 2,092 shares
@ $22.3006, valued at
$46.7k
Sold 69 shares
@ $21.5401, valued at
$1.5k
Sold 1 shares
@ $21.33, valued at
$21.3 |
|
| 12/29/2015 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Granted 70,000 options to buy
@ $21.43, valued at
$1.5M
|
|
| 12/14/2015 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Sold 2,500 shares
@ $20.4925, valued at
$51.2k
Exercised 2,500 options to buy
@ $4.56, valued at
$11.4k
|
|
| 11/12/2015 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Sold 2,500 shares
@ $21.1692, valued at
$52.9k
Exercised 2,500 options to buy
@ $4.56, valued at
$11.4k
|
|
| 10/27/2015 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Sold 5,000 shares
@ $20, valued at
$100k
Exercised 5,000 options to buy
@ $4.56, valued at
$22.8k
|
|
| 08/12/2015 |
4
| Dupont Jakob (SVP & Chief Medical Officer) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Sold 2,500 shares
@ $22.2486, valued at
$55.6k
Exercised 2,500 options to buy
@ $4.56, valued at
$11.4k
|
|
|
|
|